Loading...
Loading...
- Medtronic Plc's MDT Q1 FY22 sales of $7.9 billion increased 23% Y/Y as reported and 19% on an organic basis, beating the consensus estimate of $7.86 billion.
- Q1 adjusted EPS of $1.41 more than doubled from $0.62 a year ago, surpassing the analyst consensus of $1.32.
- Sales at Medtronic's heart devices unit jumped 19% Y/Y to $2.89 billion. Spine & neurosurgery product segment sales increased 29% to $2.20 billion.
- Related: Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
- Diabetes revenue of $572 million increased 2% as reported and declined 3% organic due to declines in U.S. sales of consumables and continuous glucose monitoring (CGM) products.
- Guidance: For FY22, Medtronic expects EPS of $5.65 - $5.75 (consensus of $5.69), compared to $5.60 - $5.75, guided earlier.
- Medtronic continues to expect revenue growth of approximately 9% on an organic basis. If current exchange rates hold, revenue growth in FY22 would be positively affected by about $100 million - $200 million.
- Price Action: MDT shares are up 1.96% at $131 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in